Precision BioSciences
Durham, North Carolina, United States · Biotechnology, Genetics, Health Care
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre
Key facts
- Headquarters
- Durham, North Carolina, United States
- Employees
- 106
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (DTIL)
- Website
- precisionbiosciences.com
- Company page
Recent activity at Precision BioSciences
- : SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for the issuance and sale of 10,235,077 shares of its common stock at a price of $7.75 per share, along with pre-funded warrants to purchase 5,893,964 shares at $7.749995 each. The expected net proceeds will enhance the company's liquidity and continue funding of its PBGENE-HBV and PBGENE-DMD clinical programs, ensuring sufficient capital into late 2029. The company anticipates that existing cash combined with the new offering will support critical next-stage developments in these programs.
- : SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for an Offering of 10,235,077 shares of its common stock at $7.75 per share, alongside pre-funded warrants for 5,893,964 shares priced at $7.749995 each. The estimated net proceeds of approximately $116.5 million will be used for R&D on PBGENE-HBV and PBGENE-DMD and for general corporate purposes. The Offering's closing is set for November 6, 2026, pending customary conditions. The agreement includes significant terms for the pre-funded warrants, detailing their exercise and adjustment in case of corporate actions, and stipulates that holders won’t receive voting rights or other privileges typical of Common Stock holders.
- : SEC 8-K (7.01): On August 24, 2026, Precision BioSciences, Inc. announced the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial, which is evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). This significant milestone took place at Arkansas Children’s Hospital, marking an important step in the clinical development of their gene therapy aimed at treating this genetic condition. The press release detailing this announcement is included as Exhibit 99.1 in the filing. This event highlights Precision BioSciences' ongoing commitment to advancing therapeutic options for patients with DMD, and is pivotal in the trajectory of their clinical program.
- : Precision BioSciences Promotes Alex Kelly to Chief Operating Officer
- : SEC 8-K (5.02):
- : SEC 8-K (8.01):
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On May 27, 2026, the Company issued a press release regarding significant new clinical data for PBGENE-HBV from the ELIMINATE-B study presented at EASL. The data indicates that PBGENE-HBV effectively eliminated cccDNA, with a 1-log reduction in cccDNA-derived transcripts and permanent inactivation of viral replication in the remaining cccDNA. Furthermore, pgRNA was confirmed as a direct biomarker for assessing treatment efficacy, with complete loss in 100% of patients showing detectable pgRNA initially. The data supports the treatment’s favorable safety profile, with no dose-limiting toxicities reported. This development is crucial for advancing clinical evaluations and therapeutic applications in treating HBV.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): Precision BioSciences, Inc. announced a Regulation FD disclosure regarding a live webcast event scheduled for March 17, 2026, at 9:00 a.m. Eastern Time. The event will feature Dr. Aravindhan Veerapandiyan and Pat Furlong discussing the current treatment landscape for Duchenne muscular dystrophy (DMD) and the PBGENE-DMD program along with the FUNCTION-DMD Phase 1/2 clinical trial. This event aims to highlight the unmet needs in DMD treatment and will be accessible through the Company's website, with the presentation materials provided as Exhibit 99.1. This disclosure is significant as it pertains to the Company's ongoing efforts and developments in DMD treatment initiatives.
Precision BioSciences funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Funding Round | $66.4M |
| Feb 2024 | Venture | $7.5M |
| Mar 2019 | Venture | $39.6M |
| Jun 2018 | Venture | $88.1M |
Leadership
- Michael Amoroso, President & CEO
- Naresh Tanna, Chief of Staff to the CEO / Commercial Head
- Buki Acipd, HRBP Director
- Shalini Sharp, Director
- Tony Yao, Director
- Robert Adelman, Director
- Derek Jantz, Executive Officer, Director
- Matthew Kane, Executive Officer, Director
- Alex Kelly, Chief Operating Officer
- Zach Stanley, Process Development
Verified email and direct lines for Precision BioSciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Precision BioSciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Precision BioSciences in the news
- Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - Precision BioSciences (May 27, 2026)
- Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer - Precision BioSciences (Oct 14, 2020)
- Precision BioSciences Appoints Alex Kelly as Chief Financial Officer - Precision BioSciences (May 27, 2021)
- Precision BioSciences Appoints Melinda Brown to Board of Directors - Precision BioSciences (May 31, 2022)
Companies similar to Precision BioSciences
- VolitionRx · Biotechnology, Genetics, Health Care, Therapeutics
- Passage Bio · Biotechnology, Genetics, Health Care, Therapeutics
- Franklin Biolabs · Biotechnology, Genetics, Health Care, Therapeutics
- Applied StemCell · Biotechnology, Genetics, Health Care, Therapeutics
- MeiraGTx Holdings plc · Biotechnology, Genetics, Health Care, Therapeutics
About Precision BioSciences: questions and answers
What does Precision BioSciences do?
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre
Where is Precision BioSciences headquartered?
Precision BioSciences is headquartered in Durham, North Carolina, United States.
How many employees does Precision BioSciences have?
Precision BioSciences has about 106 employees.
Has Precision BioSciences raised funding?
Yes. Fundz has recorded 4 funding events for Precision BioSciences. The most recent, Funding Round of $66.4M, was in Nov 2025.
Who leads Precision BioSciences?
Michael Amoroso is a President & CEO at Precision BioSciences.
What is the latest news on Precision BioSciences?
On Nov 09, 2026, SEC 8-K (8.01): On November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement for the issuance and sale of 10,235,077 shares of its common stock at a price of $7.75 per share, along with pre-funded warrants to purchase 5,893,964 shares at $7.749995 each. The expected net pr
Is Precision BioSciences a public company?
Yes. Precision BioSciences is publicly traded under the ticker DTIL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy